Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025International Journal of SurgeryOpen Access

Efficacy and safety of TACE plus lenvatinib with PD-1 inhibitor for unresectable huge hepatocellular carcinoma: a multicenter retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHui LiXLXiaohui LiRLRuixia Li

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis shows that TACE combined with lenvatinib and PD-1 improves progression-free survival and tumor response in unresectable huge HCC.

Key Points

  • TACE plus lenvatinib and PD-1 inhibitor improved progression-free survival significantly in unresectable huge HCC.
  • Median progression-free survival was 8.37 months for TACE + Len + PD-1 compared to 6.03 months for TACE + Len.
  • Analysis utilized propensity score matching and inverse probability of treatment weighting for bias reduction.
  • Triple therapy's survival benefit appears primarily linked to enhanced early tumor response.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/694023fa2d562116f28fda32https://doi.org/10.1097/js9.0000000000004131
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TACE, lenvatinib, and PD-1 inhibitors in unresectable advanced hepatocellular carcinoma: an exploratory retrospective cohort study2026
  2. 2The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study2024 · 7 citations
  3. 3TACE combined with lenvatinib and PD-1 inhibitors: a promising strategy for unresectable huge HCC2026
  4. 4Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study2026
  5. 5Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis2025 · 7 citations